Skip to content

Junior LP Foot - Clinical Investigation Protocol

Exploratory Testing of a Pediatric Foot

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06156839
Enrollment
13
Registered
2023-12-05
Start date
2024-01-08
Completion date
2024-12-10
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation

Keywords

Prosthetic Device

Brief summary

The purpose of the following study is of exploratory nature to provide design input for a prosthetic foot under development for children with lower limb loss, amputation or deficiency.

Detailed description

The purpose of the following study is of exploratory nature to provide design input for a prosthetic foot under development for children with lower limb loss, amputation or deficiency. User testing is needed to get data points for the stiffness curve of the foot. These datapoints are extrapolated from user testing and reduces the risk to design a too stiff or soft device. Machine tests cannot replace user feedback. The user´s perception helps to detect performance deficits and address these in early stages of the design. Walking performance may change if the foot is too stiff or too soft. Some of these changes can be spotted by observation through legal guardians or experienced prosthetists. Product changes may be justified based on the observations made by the child, legal guardian, Certified Prosthetist/Orthotist (CPO) or engineers specializing in foot design.

Interventions

Stiffness Testing Procedure: * Potential subjects identified, fitting inclusion/exclusion criteria, by Principle Investigator (PI). * Informed consent obtained from participant if applicable, legal guardian or both. * Subject (legal guardian) signs Informed Consent Form (ICF) * Subject ambulates on their current prescribed foot for observation - Questions administered, by PI or delegated by PI * Subject fitted with investigational device, by PI * Subject ambulates in the investigational device for observation - Questions administered, by PI or delegated by PI * Subject is fitted back to their prescribed prosthesis, by PI

Sponsors

Össur Iceland ehf
Lead SponsorINDUSTRY
Shriners Hospitals for Children
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Cognitive ability to understand all instructions and questionnaires in the study (adapted to kids). * Active prosthesis user * Transtibial or transfemoral amputation, limb loss or similar level congenital limb deficiency. * Age 5 or older. o Age 5-12 years preferred. * 15 kg \< Body weight \< 55 kg * 16 ≤ Foot size ≤ 24 * Clearance: Size 16 \> 50mm, Sizes 17-19 \> 60mm, Sizes 20-24 \> 70mm * Willing and able to participate in the study and follow the protocol, including consent to participate from legal guardian if under 16 years old.

Exclusion criteria

* Users with severe residual limb pain or socket problems, which have negative impact on testing and outcome.

Design outcomes

Primary

MeasureTime frameDescription
Overall Prosthetic Foot Stiffness2 hoursUser perception of provided prosthetic foot stiffness. Too soft good Too stiff

Secondary

MeasureTime frameDescription
Overall Prosthetic Foot Performance2 hoursUser perception of provided prosthetic foot performance.

Participant flow

Recruitment details

Recruitment took place between January and March 2024, participants recruited from clinic database.

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
12 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
1 Participants
Region of Enrollment
United States
13 Participants
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
7 Participants
Weight38.3 kilogram
STANDARD_DEVIATION 12

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 13
other
Total, other adverse events
0 / 13
serious
Total, serious adverse events
0 / 13

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026